Prosecution Insights
Last updated: October 02, 2026

Examiner: MCMILLIAN, KARA RENITA

Tech Center 1600 • Art Units: 1617 1622 1623 1627

This examiner grants 31% of resolved cases

Analysis

Kara Renita McMillian is a patent examiner in Tech Center 1600, working within Art Unit 1617. The examiner has 976 resolved cases and an allowance rate of 30.7 percent. This 30.7 percent rate reflects the proportion of applications that reach a grant. For the 976 cases handled, this data provides a basis for understanding the probability of success during the examination process. The volume of resolved cases reflects the examiner's experience within Tech Center 1600.

The median days to allowance for this examiner is 1340. This 1340-day timeline represents the duration for an application to move from filing to a grant. Applicants should consider this period when planning their patent strategy and resource allocation. The volume of 976 resolved cases suggests that this duration is a consistent aspect of the examiner's workflow in Art Unit 1617. This median provides a specific metric for evaluating the expected length of prosecution.

The data shows an interview lift of 37.9 percent. This 37.9 percent lift represents the change in the likelihood of allowance when an interview is conducted. It suggests that direct communication is a method for addressing the probability of a grant. For practitioners, utilizing an interview is an option to navigate the prosecution process and achieve a positive outcome. Practitioners can use this lift to evaluate the potential benefits of direct engagement.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Performance Statistics

30.7%
Allow Rate
-29.3% vs TC avg
1,042
Total Applications
+37.9%
Interview Lift
1340
Avg Prosecution Days
Based on 976 resolved cases, 2023–2026

Rejection Statute Breakdown

2.2%
§101 Eligibility
10.2%
§102 Novelty
47.6%
§103 Obviousness
17.8%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19303084 SOLID R-BETA-HYDROXYBUTYRIC ACID COMPOSITION Non-Final OA AXCESS GLOBAL SCIENCES, LLC
17783220 PARASITE CONTROL IN RUMINANTS Final Rejection Intervet Inc.
17625425 LONGEVITY SIGNATURES AND THEIR APPLICATIONS Final Rejection The Brigham and Women's Hospital, Inc.
17904388 AGENTS FOR USE IN THE TREATMENT OF TISSUE DAMAGE Non-Final OA UCL BUSINESS LTD
17616248 NOVEL SPIROBICYCLIC INTERMEDIATES Non-Final OA Janssen Pharmaceutica NV
17530402 COMPOSITIONS AND METHODS FOR CANCER EXPRESSING PDE3A OR SLFN12 Final Rejection Bayer Pharma Aktiengesellschaft
18284897 NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF Non-Final OA Jacobio Pharmaceuticals Co., Ltd.
18633164 COMBINATION OF BI853520 WITH CHEMOTHERAPEUTIC DRUGS Non-Final OA INXMED (NANJING) CO., LTD.
18284416 COMPOUND 7AI IN TREATING EWING SARCOMA BY INHIBITING OTUD7A Non-Final OA Atomwise Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month